The Value of Microbes in Cancer Neoantigen Immunotherapy

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 Aug 26

PMID 37631352

Authors

Junrui Tian

Jian Ma

Affiliations

Soon will be listed here.

Abstract

Tumor neoantigens are widely used in cancer immunotherapy, and a growing body of research suggests that microbes play an important role in these neoantigen-based immunotherapeutic processes. The human body and its surrounding environment are filled with a large number of microbes that are in long-term interaction with the organism. The microbiota can modulate our immune system, help activate neoantigen-reactive T cells, and play a great role in the process of targeting tumor neoantigens for therapy. Recent studies have revealed the interconnection between microbes and neoantigens, which can cross-react with each other through molecular mimicry, providing theoretical guidance for more relevant studies. The current applications of microbes in immunotherapy against tumor neoantigens are mainly focused on cancer vaccine development and immunotherapy with immune checkpoint inhibitors. This article summarizes the related fields and suggests the importance of microbes in immunotherapy against neoantigens.

Citing Articles

Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer.

Talpin A, Maia A, Carpier J, Kulakowski G, Aubergeon L, Kervevan J J Immunother Cancer. 2025; 13(2).

PMID: 39979071 PMC: 11842988. DOI: 10.1136/jitc-2024-010192.

Harnessing microbial antigens as cancer antigens: a promising avenue for cancer immunotherapy.

Zhang T, Zhang X, Chen J, Zhang X, Zhang Y Front Immunol. 2024; 15:1411490.

PMID: 39139570 PMC: 11319170. DOI: 10.3389/fimmu.2024.1411490.

References

Finn O, Rammensee H . Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens: Nothing New in Spite of the Name. Cold Spring Harb Perspect Biol. 2017; 10(11). PMC: 6211383. DOI: 10.1101/cshperspect.a028829. View

Roy S, Trinchieri G . Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017; 17(5):271-285. DOI: 10.1038/nrc.2017.13. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Nagel R, Pataskar A, Champagne J, Agami R . Boosting Antitumor Immunity with an Expanded Neoepitope Landscape. Cancer Res. 2022; 82(20):3637-3649. PMC: 9574376. DOI: 10.1158/0008-5472.CAN-22-1525. View

Simoni Y, Becht E, Fehlings M, Loh C, Koo S, Teng K . Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018; 557(7706):575-579. DOI: 10.1038/s41586-018-0130-2. View

Xu H, Cao C, Ren Y, Weng S, Liu L, Guo C . Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment. Front Immunol. 2022; 13:949490. PMC: 9513044. DOI: 10.3389/fimmu.2022.949490. View

Chiaro J, Kasanen H, Whalley T, Capasso C, Gronholm M, Feola S . Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma. Cancer Immunol Res. 2021; 9(8):981-993. PMC: 8974425. DOI: 10.1158/2326-6066.CIR-20-0814. View

Huang Y, Fan X, Wang Z, Zhou J, Tian X, Li N . Identification of helicobacter species in human liver samples from patients with primary hepatocellular carcinoma. J Clin Pathol. 2004; 57(12):1273-7. PMC: 1770525. DOI: 10.1136/jcp.2004.018556. View

Polyakova A, Kuznetsova K, Moshkovskii S . Proteogenomics meets cancer immunology: mass spectrometric discovery and analysis of neoantigens. Expert Rev Proteomics. 2015; 12(5):533-41. DOI: 10.1586/14789450.2015.1070100. View

10.

Gros A, Parkhurst M, Tran E, Pasetto A, Robbins P, Ilyas S . Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016; 22(4):433-8. PMC: 7446107. DOI: 10.1038/nm.4051. View

11.

Baruch E, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L . Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2020; 371(6529):602-609. DOI: 10.1126/science.abb5920. View

12.

Hu Z, Ott P, Wu C . Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2017; 18(3):168-182. PMC: 6508552. DOI: 10.1038/nri.2017.131. View

13.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

14.

Abbott M, Ustoyev Y . Cancer and the Immune System: The History and Background of Immunotherapy. Semin Oncol Nurs. 2019; 35(5):150923. DOI: 10.1016/j.soncn.2019.08.002. View

15.

Ferreira J, Relvas-Santos M, Peixoto A, Silva A, Santos L . Glycoproteogenomics: Setting the Course for Next-generation Cancer Neoantigen Discovery for Cancer Vaccines. Genomics Proteomics Bioinformatics. 2021; 19(1):25-43. PMC: 8498922. DOI: 10.1016/j.gpb.2021.03.005. View

16.

Gubin M, Zhang X, Schuster H, Caron E, Ward J, Noguchi T . Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515(7528):577-81. PMC: 4279952. DOI: 10.1038/nature13988. View

17.

Sahin U, Tureci O . Personalized vaccines for cancer immunotherapy. Science. 2018; 359(6382):1355-1360. DOI: 10.1126/science.aar7112. View

18.

Zhang X, Qi Y, Zhang Q, Liu W . Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy. Biomed Pharmacother. 2019; 120:109542. DOI: 10.1016/j.biopha.2019.109542. View

19.

Boesch M, Baty F, Rothschild S, Tamm M, Joerger M, Fruh M . Tumour neoantigen mimicry by microbial species in cancer immunotherapy. Br J Cancer. 2021; 125(3):313-323. PMC: 8329167. DOI: 10.1038/s41416-021-01365-2. View

20.

Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D . Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer. 2019; 7(1):193. PMC: 6651993. DOI: 10.1186/s40425-019-0650-9. View